Jaguar Health, Inc. is a commercial-stage pharmaceuticals company specializing in plant-based prescription medicines for gastrointestinal distress in people and animals. It operates through two primary segments: Animal Health and Human Health, developing and commercializing products for companion animals, production animals, and humans. Key offerings include Mytesi, an anti-secretory antidiarrheal drug for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, and Canalevia-CA1, a prescription product for chemotherapy-induced diarrhea in dogs. The company is advancing Crofelemer in Phase III trials for prophylaxis of diarrhea in adult cancer patients, as well as Phase II trials for conditions like short bowel syndrome, microvillus inclusion disease, diarrhea-predominant irritable bowel syndrome, and idiopathic diarrhea. Additionally, Mytesi is in Phase III for cancer therapy-related diarrhea and Phase II for irritable bowel syndrome, while NP-300, a second-generation antidiarrheal, is in Phase I for moderate-to-severe diarrhea. Headquartered in San Francisco, California, Jaguar Health, Inc. plays a focused role in addressing unmet needs in gastrointestinal health across human and veterinary markets.